DocWire News Editors

DocwireNews

Researchers sought to assess real-world costs associated with the oral agent apremilast for the treatment of biologic-naïve and biologic-experienced patients with psoriasis compared with biologic therapy. The results of the study were presented at the AMCP Annual Meeting during a poster session titled “Comparison of Real-World Healthcare Costs Among Psoriasis Patients Initiating Apremilast or Biologics.”
The researchers included adult patients with psoriasis who had initiated apremilast (n=408) or a biologic agent (n=810) between January 1, 2014, and December 31, 2015, and had 12 months of pre- and post-index continuous enrollment in the Optum Clinformatics claims database.
The mean patient age was 50 years, and the mean Charlson Comorbidity Index score was 0.6.
While persistent on therapy (defined as continuous treatment without a &gt;60-day gap or a switch to another treatment during the 12-month post-index period), per-patient, per-month (PPPM) total healthcare costs (defined as inpatient, outpatient, and outpatient pharmacy costs that were based on standard prices in the Optum Clinformatics Data Mart database) were significantly lower among patients receiving apremilast ($2,215) compared with those receiving a biologic ($5,267; P&lt;0.0001). The researchers said this was driven by significantly lower PPPM outpatient pharmacy costs associated with apremilast ($1,803 vs $4,536; P&lt;0.0001) and significantly lower PPPM outpatient medical costs ($337 vs $466; P&lt;0.001). PPPM inpatient medical costs were similar between the apremilast ($75) and biologic ($266) cohorts (P=0.685).
During the 12-month post-index period, total outpatient pharmacy costs ($17,504 vs $34,293; P&lt;0.0001), total outpatient medical costs ($4,509 vs $5,971; P=0.011), and total healthcare costs ($22,827 vs $42,606; P&lt;0.0001) were significantly lower for the apremilast versus biologic cohort.
The study was sponsored by Celgene.
Wu J, Pelletier C, Ung B, Ni Q, Tian M. Comparison of Real-World Healthcare Costs Among Psoriasis Patients Initiating Apremilast or Biologics. Abstract L16. Presented at the AMCP Managed Care &amp; Specialty Pharmacy Annual Meeting, April 23-26; Boston, MA.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Study Compares Cost of Apremilast Versus Biologics for Patients with Psoriasis

AMCP 2018

Researchers sought to assess real-world costs associated with the oral agent apremilast for the treatment of biologic-naïve and biologic-experienced patients with psoriasis ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe